Major adverse cardiovascular events in advanced-stage lung cancer: a multicenter cohort study.
Chih-Hao ChangShih-Hao HuangHung-Yu HuangMeng-Hung LinChung-Shu LeeHsin-Fu LeeJason Chia-Hsun HsiehChun-Yu ChengPublished in: Therapeutic advances in medical oncology (2024)
MACEs are common in patients with advanced-stage lung cancer during treatment. The incidence of MACE was similar between the first-line EGFR-TKI therapy and first-line chemotherapy groups. Although more patients in the EGFR-TKI group were female and never-smokers, the risk of ischemic stroke was higher in patients who received first-line EGFR-TKI therapy than in those who received first-line chemotherapy.
Keyphrases
- tyrosine kinase
- epidermal growth factor receptor
- cardiovascular events
- small cell lung cancer
- advanced non small cell lung cancer
- end stage renal disease
- coronary artery disease
- ejection fraction
- chronic kidney disease
- locally advanced
- newly diagnosed
- cardiovascular disease
- prognostic factors
- risk factors
- chronic myeloid leukemia
- peritoneal dialysis
- emergency department
- cross sectional
- stem cells
- clinical trial
- radiation therapy
- smoking cessation
- mesenchymal stem cells
- patient reported outcomes
- bone marrow
- drug induced